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Abstract
In this study we profile free 3-oxo sterols present in plasma from patients affected with the
neurodegenerative disorder of sterol and bile acid metabolism cerebrotendinous xanthomatosis
(CTX), utilizing a combination of charge-tagging and LC-ESI-MSn performed with an LTQ-
Orbitrap Discovery instrument. In addition, we profile sterols in plasma from 24 month old
cyp27A1 gene knockout mice lacking the enzyme defective in CTX. Charge-tagging was
accomplished by reaction with cationic Girard's P (GP) reagent 1-(carboxymethyl) pyridinium
chloride hydrazide, an approach uniquely suited to studying the 3-oxo sterols that accumulate in
CTX, as Girard's reagent reacts with the sterol oxo moiety to form charged hydrazone derivatives.
The ability to selectively generate GP-tagged 3-oxo-4-ene and 3-oxo-5(H) saturated plasma sterols
enabled ESI-MSn analysis of these sterols in the presence of a large excess (3 orders of
magnitude) of cholesterol. Often cholesterol detected in biological samples makes it challenging to
quantify minor sterols, with cholesterol frequently removed prior to analysis. We derivatized
plasma (10μl) without SPE removal of cholesterol to ensure detection of all sterols - present in
plasma. We were able to measure 4-cholesten-3-one in plasma from untreated CTX patients (1207
± 302 ng/ml, mean ± SD, n=4), as well as other intermediates in a proposed pathway to 5αa-
cholestanol. In addition, a number of bile acid precursors were identified in plasma using this
technique. GP-tagged sterols were identified utilizing high resolution exact mass spectra (± 5
ppm), as well as MS2 ([M]+→) spectra that possessed characteristic neutral loss of 79 Da
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(pyridine) fragment ions, and MS3 ([M]+→[M-79]+→) spectra that provided additional
structurally informative fragment ions.
1. Introduction
Cerebrotendinous xanthomatosis (CTX; OMIM#213700) is a rare genetic disorder
associated with deficient sterol 27-hydroxylase (CYP27A1); an enzyme important in the
conversion of cholesterol to cholic and chenodeoxycholic acid (CDCA) (Figure 1 neutral
pathway to primary bile acids). A damaging consequence of CYP27A1 deficiency is the
accumulation of 5α-cholestanol (a 5α-dihydro derivative of cholesterol) in the tissues of
affected patients. Patients often develop 5α-cholestanol and cholesterol containing
xanthomas. Extensive deposition of 5α-cholestanol in the brain [1], is associated with the
development of severe neurological dysfunction.-. In addition to 5α-cholestanol, tissues and
blood from untreated CTX patients contain high concentrations of bile acid precursors, in
particular 7α-hydroxy-4-cholesten-3-one (C4-7α-ol-3-one, see Figure 1) [2–8].
The data reported thus far suggest that a major synthetic pathway to 5α-cholestanol in CTX
patients originates from C4-7α-ol-3-one [9], in contrast to a normal synthetic pathway that
originates from cholesterol. Both pathways for 5α-cholestanol synthesis appear to converge
through 4-cholesten-3-one (C4-3-one, Figure 1). In vivo studies in CTX patients
demonstrated the formation of biliary 5α-cholestanol from intravenous dosed [14C]-labeled
C4-3-one [10]. Studies in rabbits [11] and in rats [12] demonstrated that 5α-cholestanol was
rapidly found in circulation after oral dosing with [14C]-labeled C4-3-one. Interestingly,
prolonged feeding of C4-3-one (0.5%) in birds resulted in severe aortic arteriosclerosis and
the accumulation of large amounts of 5α-cholestanol in blood and tissues [12,13]. The
synthesis of 5α-cholestanol from C4-3-one was demonstrated to occur via 5α-cholestan-3-
one under in vitro conditions utilizing animal liver tissue preparations [14,15].
Although in vitro experiments initially suggested C4-3-one was formed from cholesterol in
CTX [10], more recent studies indicate a major pathway to C4-3-one in CTX from 4,6-
cholestadiene-3-one produced from C4-7α-ol-3-one (Figure 1) [2,7]. High concentrations of
4,6-cholestadiene-3-one (500–850ng/ml) were shown to be present in hydrolyzed serum
from untreated CTX patients [2], and the turnover of 4,6-cholestadiene-3-one to C4-3-one
and 5α-cholestanol was demonstrated in liver and brain tissue studies [16]. Although C4-7α-
ol-3-one can undergo non-enzyme catalyzed dehydration to form 4,6-cholestadiene-3-one, in
vitro studies with liver tissue have characterized enzymatic conversion of C4-7α-ol-3-one to
4,6-cholestadiene-3-one and subsequent saturation of the Δ-6 double bond to form C4-3-one
[3,17].
To provide insight into alternate pathways that may be accentuated when bile acid synthesis
is perturbed in CTX, we hypothesized a recently described approach utilizing the hybrid
Thermo LTQ-Orbitrap instrument coupled with sterol derivatization [18] could be utilized
for highly sensitive, selective ESI-MSn analysis of 3-oxo-4-ene sterols present in blood and
tissues of CTX patients. The approach involves sterol derivatization with cationic Girard's P
(GP) reagent to enhance ESI ionization, as well as to provide MS2 ([M]+→) spectra
fragment ions possessing characteristic GP derivative neutral losses of 79 and 107 Da
[18,19] and MS3 ([M]+→[M-79]+→) spectra fragment ions that provide further structural
information. The Girard derivatives are resolved using HPLC and are identified by exact
mass analysis (± 5 ppm), with MS2 and MS3 spectra obtained to confirm sterol identity.
Exact mass data is generated in the Orbitrap mass analyzer and MSn spectra are generated in
the LTQ linear ion trap (LIT) mass analyzer. We set out to detect sterols possessing a 3-
oxo-4-ene or 3-oxo-5(H) saturated structure proposed to be in vivo intermediates in CTX
                     
                                                                                               
 
  
            
         
 
  
            
         
 
  
            
         
biochemical pathways (Figure 1) in a targeted manner utilizing derivatization with GP
reagent and LC-ESI-MSn analysis with an LTQ-Orbitrap Discovery instrument. We
undertook this effort as part of a larger project designed to investigate altered metabolic
pathways in CTX, in order to develop improved methods of screening, diagnosis, and
treatment for this disorder. We describe here profiling of the free 3-oxo sterols present in
plasma from affected patients and from 24 month old cyp27A1 gene knock out (cyp27A1 −/
−) mice deficient in sterol 27-hydroxylase, the enzyme defective in CTX [5,20,21]. Bile acid
precursors are elevated in these mice, which display a 3–5 fold increase in cholesterol 7α-
hydroxylase activity [22]. Although large amounts of C4-7α-ol-3-one are present in liver
tissue and blood from the mice [5,20], they do not develop xanthomas, or accumulate 5α-
cholestanol to the extent observed in human disease [5,5,22,23]. Recently significant
cerebral accumulation of 5α-cholestanol was noted to occur in 12 month old cyp27A1 −/
−mice, especially in female mice [20], although corresponding to only 3% of the sterol pool
versus 20–40% in patients with CTX [24]. The cyp27A1 −/− mice were used to demonstrate
formation of cerebral 5α-cholestanol from intravenously dosed [2H]-labeled C4-7α-ol-3-one
[20].
To summarize, in this study we report on the utility of GP derivatization and high resolution
exact mass LC-ESI-MSn analysis for profiling the free 3-oxo sterols present in plasma from
untreated CTX patients and cyp27A1 −/− mice. We previously examined the utility of GP
derivatization for quantitative LC-ESI-MS2 analysis of a specific 3-oxo-4-ene sterol
elevated in plasma from CTX patients [2–8]; C4-7α-ol-3-one. We found C4-7α-ol-3-one
demonstrated improved utility as a diagnostic marker of disease and to monitor treatment
compared to 5α-cholestanol [8]. We anticipate GP-tagged sterols identified with high
resolution exact mass LCESI-MSn analysis will be amenable to LC-ESI-MS2
analysisperformed with unit resolution instrumentation as previously described for C4-7α-
ol-3-one [8], and we describe here preliminary LC-ESI-MS2 experiments to measure 5α-
cholestanol precursors We discuss our results in relation to the alternate pathways utilized
when bile acid synthesis is perturbed in CTX and in the cyp27A1 −/− mouse.
2. Experimental
2.1 Chemicals and reagents
4,6-Cholestadiene-3-one, 5α-cholestan-3β-ol (5α-cholestanol), 5α-cholestan-3-one, 4-
cholesten-3-one (C4-3-one), cholesterol (5-cholesten-3β-ol), 7α-hydroxy-4-cholesten-3-one
(C4-7α-ol-3-one) and 3α,7α,12α-trihydroxy-5β-cholestane were from Steraloids (Newport,
RI). 5β-Cholestan-3α-ol (5β-cholestanol) was obtained from Sigma-Aldrich (St Louis, MO).
7α,12α-dihydroxy-5β-cholestan-3-one was synthesized from 3α,7α,12α-trihydroxy-5β-
cholestane using 3α-hydroxysteroid dehydrogenase from Sigma-Aldrich in the presence of
β-NAD [25]. C4-7α-ol-3-one-d7 and C4-3-one-d7 internal standards were synthesized from
their respective 3β-hydroxy-Δ5 analogues using stretomyces sp. cholesterol oxidase obtained
from Sigma-Aldrich as described previously [8,26,27]. 7α-Hydroxycholesterol-d7 and
cholesterol-d7 were obtained from CDN Isotopes (Pointe-Claire, Quebec, Canada).
Methanol and water (GC-MS grade) were from Burdick and Jackson (Muskegon, MI).
Formic acid (90%) was J.T. Baker brand and glacial acetic acid (99.99%) was from Aldrich.
`Girard's reagent P' (1-(carboxymethyl)pyridinium chloride hydrazide) was obtained from
TCI America (Portland, OR). Volume 0.5ml Ultrafree-MC centrifugal filters (0.45 mm)
were from Millipore (Bedford, MA). Human pooled plasma (K2EDTA) was purchased from
Biological Specialty Corporation (Colmar, PA).
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2.2 Human and animal studies
Informed consent was obtained from the CTX patients and patient study protocols were
approved by the Oregon Health & Science University Institutional Review Board. Blood
samples were collected from untreated patients aged >16 years (n=4). Blood was collected
from both male and female cyp27A1 gene knock out mice and their wild type littermates -at
24 months of age. Plasma (K2EDTA) was separated from the blood samples and stored at
−80°C. The cyp27A1 −/− and cyp27A1 wild type (+/+) mice were from a heterozygote
breeding colony at the Department of Veterans Affairs Medical Center San Francisco
(VAMC), which was transferred onto the C57BL/6J background by backcrossing more than
ten generations [22]. Mouse study protocols were approved by the Animal Studies
Subcommittee, VAMC San Francisco. The animals were maintained on rodent chow and fed
ad libitum. The Animal Research Facility at VAMC San Francisco is specific pathogen free
and is `Association for Assessment and Accreditation of Laboratory Animal Care
International' accredited.
2.3 Preparation of calibrators and samples
Calibrators for the GC-FID and GC-MS methods were generated using dilutions of
cholesterol and 5α-cholestanol authentic standard in n-propyl alcohol or chloroform. To
measure cholesterol and 5α-cholestanol, plasma samples (25 to 100 μl) were spiked with
internal standard (5β-cholestanol), hydrolyzed, extracted and derivatized to form
trimethylsilyl ethers. GC was performed using a Phenomenex ZB1701 column (30m,
ID=0.25mm, 0.25μm) with the method temperature held at 170°C for 2 min, the temperature
increased at 18°C/min to 260°C, the temperature held for 12min and increased at 3C°/min to
280°C. Cholesterol was analyzed by FID and cholestanol by SIM MS; with detection of an
m/z =355.4 target ion for internal standard and m/z = 306.3 ion for 5α-cholestanol.
Calibrators for the LC-ESI-MS methods were generated using dilutions of C4-7α-ol-3-one,
C4-3-one and 5α-cholestan-3-one authentic standard in methanol or by spiking
commercially available plasma with authentic standard solution. After addition of 20 μl of
methanol containing C4-7α-ol-3-one-d7 (10 ng) and C4-3-one-d7 (10 ng) internal standards,
sterols present in calibrators or 10 μl plasma samples were derivatized with 175 μl of 10 mM
GP reagent in methanol at 1% acetic acid. The samples were shaken (200 rpm) for 120 min
at room temperature and for plasma samples the precipitate was removed using centrifugal
filters (0.45 μm) prior to LC-ESI-MSn analysis.
2.4 LC-ESI-MSn
GP-tagged sterols were resolved using an Accela UPLC system (Thermo Fisher, San Jose,
CA) with sample injection volume of 10 μl. Samples were injected onto a Michrom
BioResources (Auburn, CA) trap C18 cartridge that was subsequently washed at 0.2 ml/min
to remove excess GP reagent with solvent consisting of 33% methanol, 17% acetonitrile and
50% water. After 2 min the GP-tagged sterols were back-flushed onto a 50×2.1 mm, 1.9 μm,
Hypersil Gold C18-HPLC column from Thermo Hypersil (Waltham, MA, USA). The
gradient mobile phase for HPLC separation (modified from Ogundare et al [28]) was
delivered at 0.2 ml/min and consisted of two solvents (both containing 0.1% formic acid); A
consisting of 33% methanol, 17% acetonitrile and 50% water and B consisting of 63%
methanol, 32% acetonitrile, 5% water. Solvent B was increased from 25% to 100% over 3
min. The column was kept at 100% B for 6 min prior to increasing the flow to 0.25 ml/min
for 2 min. The column was then equilibrated at 0% B for 2 min at 0.25 ml/min, giving a total
run time of 15 min. The HPLC eluent was directed to a LTQ-Orbitrap XL Discovery
instrument (San Jose, CA, USA), equipped with an ESI ion max source. The ionization
interface was operated in the positive mode using the following settings: source voltage, 4
kV; sheath and aux gas flow rates, 50 and 5 units respectively; tube lens voltage, 90 V;
capillary voltage, 49 V; and capillary temperature, 300°C. The Orbitrap mass analyzer was
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externally calibrated prior to analysis to obtain mass accuracy within ± 5 ppm. An LC-ESI-
MSn method was created to perform three scan events in a data dependent manner as
described by Griffiths et al [18]; a high resolution (30,000) full scan event over the m/z
range 600–800 utilizing the Orbitrap analyzer, followed by data-dependent MS2 and MS3
events performed in the LIT. For the MS2 and MS3 events the normalized collision energies
were 30 % and 35 %, respectively. A precursor ion inclusion list was generated based on the
m/z of [M]+ ions for GP derivatives of potential sterols present, and MS2 spectra were
collected if precursor ions were present in the full scan spectra above a threshold of 500
counts. If a [M-79]+ fragment ion was observed in MS2 spectra above a threshold of 200
counts, MS3 spectra were collected for the [M-79]+ ion.
Plasma GP-tagged C4-7α-ol-3-one, C4-3-one and 5α-cholestan-3-one were quantified using
calibrators and high resolution data generated with the Orbitrap analyzer or LC-ESI-MS2
data generated with an Applied Biosystems/SCIEX 4000 QTRAP instrument (Foster City,
CA) scanning in triple quadrupole mode. The TurboIonSpray® ESI interface was operated
in the positive mode with settings similar to those previously described for detection of GP-
tagged C4-7α-ol-3-one [8]. The MRM transitions monitored for GP-tagged C4-7α-ol-3-one,
C4-3-one and 5α-cholestan-3-one were m/z 534.4→455.4, m/z 518.4→439.4 and m/z
520.4→441.4, respectively. Collision energies were 40 V, dwell times were 75 ms, and Q1
and Q3 were operated at unit resolution. The UPLC-ESI-MS2 system was composed of an
in-line Shimadzu (Columbia, MD) SIL-20AC XR auto-sampler and 2 LC-20AD XR LC
pumps. GP-tagged sterols were resolved with a gradient mobile phase (consisting of water
and methanol at 0.1% formic acid) as previously described [8], using a 30×2.1 mm, 1.9 μm
Hypersil Gold C18-HPLC column with a 10×2.1 mm, 3 μm Betabasic C18-guard from
Thermo Hypersil. LC-APCI-MS2 analysis of underivatized C4-7α-ol-3-one was performed
with the 4000 QTRAP instrument to assess the signal enhancement factor for GP
derivatization. The ionization interface was operated in the positive mode using the
following settings: source temp (TEM), 450°C, ion spray needle voltage (IS), 5.0 kV;
curtain (CUR), heater (GS1) and nebulizer (GS2) nitrogen gas flow rates, 15, 55 and 20 psi
respectively; declustering potential (DP), 91 V; entrance potential (EP), 10 V; and collision
cell exit potential (CXP), 24 V. The MRM transition monitored for was m/z 401.3→383.3.
The collision energy (CE) was 25 V, dwell time was 100 ms and Q1 and Q3 were operated
at unit resolution. The LC-MS2 system was equipped with a 100×2.1 (i.d.) mm, 5 μm
Betabasic C18-HPLC column with a 10×2.1 mm, 5 μm Betabasic C18-guard from
ThermoHypersil. The gradient mobile phase was delivered at a flow rate of 0.4 ml/minute.
The mobile phase consisted of two solvents: A, water and 0.1% formic acid, and B,
methanol, 5mM ammonium acetate and 0.1% formic acid. Solvent B was increased from
60–98% over 2 min, the column was washed at 98% B for 3 min and re-equilibrated at 60%
B for 3 min. The LC column temperature was kept at 40°C using a Shimadzu CTO-20AC
column oven.
3. Results
3.1 Derivatization and LC-ESI-MSn methodology
Derivatization of plasma sterols with 10 mM GP reagent in methanol containing 1% acetic
acid was performed for 120 min [8], after which time the reaction mixture was injected for
automated C18-solid phase extraction (SPE) to remove excess derivatization reagent, with
subsequent back-flushing of GP-tagged sterols onto a reversed phase C18-HPLC column for
chromatographic separation. Although the removal of plasma cholesterol prior to
derivatization with an additional SPE step minimizes generation of cholesterol auto-
oxidation products [29], we chose to perform our analysis without this step to ensure
detection of sterols that otherwise may have been removed alongside the cholesterol.
Detection of GP-tagged C4-7α-ol-3-one in plasma from a representative untreated CTX
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patient and cyp27A1 −/− mouse is shown with reconstructed ion chromatograms (RICs ± 5
ppm) derived from data generated in the Orbitrap mass analyzer (Figure 2, upper RIC for
CTX plasma, Panel C, and upper RIC for female cyp27A1 −/− mouse plasma, Panel D). In
addition to expected presence of C4-7α-ol-3-one, we detected C4-3-one at elevated
concentrations, particularly in the CTX plasma (Figure 2, upper RIC for CTX plasma, Panel
G, and upper RIC for cyp27A1 −/− mouse plasma, Panel H). Fragmentation routes for GP-
tagged sterols are illustrated by the MS2 and MS3 spectra obtained for C4-3-one (Figure 3; a
major [M-79]+ fragment ion is observed in MS2 ([M]+→) spectra, structurally informative
fragment ions are observed in MS3 ([M]+→[M-79]+→) spectra). GP-tagged sterols were
identified by comparison to authentic standard where available (for example with 5α-
cholestan-3-one, Figure 4) and by exact mass and MSn data where no standard was available
(for example with 7α,12α-dihydroxy-4-cholesten-3-one, Figure 5).
3.2 Quantification
For the profiling experiments performed with the LTQ-Orbitrap Discovery a semi-
quantitative determination of concentration was made for most compounds listed in Table 1,
by isotope dilution mass spectrometry against known amounts of [2H]7-labeled C4-7α-ol-3-
one and C4-3-one internal standards. Peak areas obtained from RICs (± 5 ppm) generated in
the Orbitrap were used to calculate the concentration for GP-tagged 3-oxo-4-ene sterols
according to equation: analyte peak area/IS peak area= analyte concentration/IS
concentration. This equation is valid as GP-tagged 3-oxo-4-ene sterols have been shown to
have an identical response factor [30]. For GP-tagged 3-oxo-5(H) saturated sterols the
calculated concentrations were normalized to the response factor for 5α-cholestan-3-one
according to the equation: (analyte peak area/IS peak area)/(5α-cholestan-3-one peak area/IS
peak area) = analyte concentration/IS concentration. Concentrations were determined for
C4-7α-ol-3-one, C4-3-one and 5α-cholestan-3-one by generating calibration curves.
Acceptable linearity (up to 10,000 ng/ml for C4-7α-ol-3-one and 2,000 ng/ml for C4-3-one
and 5α-cholestan-3-one) was demonstrated for each calibration curve with characteristic
correlation coefficients (r2) >0.95. The within-run precision (RSD) for calculated GP
derivative concentration from replicate analyses of a CTX sample is shown in Table 1.
We previously fully validated an LC-ESI-MS2 method for quantification of GP-tagged
C4-7α-ol-3-one in CTX plasma with a 4000 QTRAP operating in triple quadrupole mode
[8]. We modified this method to include quantification of GP-tagged C4-3-one and 5α-
cholestan-3-one in CTX patient and cyp27A1 −/− mouse plasma. Calibration curves were
generated by performing a least-squares linear regression for calibrant peak area ratios
obtained (sterol peak area/C4-3-one-d7 peak area) versus concentration in ng/ml plasma.
Acceptable linearity was demonstrated for each calibration curve (up to 2,000 ng/ml) with
characteristic correlation coefficients (r2) >0.95. Plasma calibrators were included with each
sample set and monitored over a month (RSD for all calibrators apart from LLOQ was
<15% and accuracy was between 85–115%; data not shown). The LLOQ (with RSD <20%)
for C4-3-one was 50 ng/ml and for 5α-cholestan-3-one was 100 ng/ml. To determine the
effect of plasma matrix on detection of GP-tagged sterols, authentic standards were
derivatized in the presence of commercially available plasma, and the ion abundance
detected was compared to the ion abundance detected for authentic standard derivatized
without plasma. Signal recovery was >80%, similar to results we previously observed for
C4-7α-ol-3-one [8].
3.3 Applications of the methodology
We hypothesized derivatization with GP reagent would provide a window with which to
examine the 3-oxo sterols that accumulate in CTX (Figure 1) as Girard's reagent reacts with
the sterol oxo moiety to enable selective ESI-MSn analysis of these sterols. We profiled the
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3-oxo-4-ene and 3-oxo-5(H) saturated sterols present in plasma from a representative
untreated CTX patient and cyp27A1 −/− mice using GP derivatization and LC-ESI-MSn
analysis and were able to obtain semi-quantitative concentration estimates from data
generated in the Orbitrap (data for cyp27A1 −/− mice shown in Table 1). The most
noticeable gender difference was a higher concentration of bile acid precursors C4-7α-ol-3-
one and 7α-hydroxy-5β-cholestan-3-one in plasma from female cyp27A1 −/− mice.We
found concentrations of C4-7α-ol-3-one and 7α-hydroxy-5β-cholestan-3-one to be fairly
comparable in cyp27A1 −/− mice and in the CTX patient (see also Figure 2).
Concentrations of 12α-hydroxylated bile acid precursors were markedly lower in cyp27A1
−/− mouse plasma compared to those in the CTX patient, although they were elevated
compared to cyp27A1 wild type littermates (data not shown). Concentrations of plasma 4,6-
cholestadiene-3-one, C4-3-one and 5α-cholestan-3-one in the cyp27A1 −/− mice were
between 9 and 15% of those in the CTX patient.
We further quantified plasma C4-7α-ol-3-one, C4-3-one and 5α-cholestan-3-one for a
number of untreated CTX patients and female and male cyp27A1 −/− and cyp27A1 wild
type mice via LC-ESI-MS2 analysis performed with a 4000 QTRAP instrument and, in
addition, quantified 5α-cholestanol and cholesterol in the plasma samples using GC-
methodology (Table 2). The mean plasma C4-7α-ol-3-one, C4-3-one and 5α-cholestan-3-
one concentrations obtained were similar to those determined from Orbitrap data, with the
mean concentration of C4-7α-ol-3-one in the cyp27A1 −/− mice being 52% of the
concentration in CTX patients, but 14.9-fold increased compared to wild type mice
(P=0.016). The concentrations of C4-3-one and 5α-cholestan-3-one in the cyp27A1 −/−
mice were <25% of the concentrations in CTX patients, with C4-3-one increased 4.7-fold
(P=0.003) and 5α-cholestan-3-one increased 1.7-fold (P=0.016) compared to wild type mice.
The mean concentration of 5α-cholestanol in the cyp27a−/− mice was 17% the
concentration in CTX patients, but 1.6-fold increased compared to wild type mice
(P=0.010).
4. Discussion
We present here an example of incorporating a derivatization step for analysis with ESI-
MSn, not only to improve analytical sensitivity, but also to tag a specific class of molecules
present in a genetic disorder. The selective generation of GP-tagged 3-oxo-4-ene and 3-
oxo-5(H) saturated plasma sterols enabled ESI-MSn detection of proposed in vivo sterol
intermediates in CTX biochemical pathways (shown in grey, Figure 1). Sterol detection was
accomplished with good sensitivity using conventional HPLC-ESI methodology, despite the
presence of a large excess of cholesterol. The signal enhancement factor for Girard
derivatization of C4-7α-ol-3-one and analysis with ESI-MS/MS relative to analysis of
underivatized C4-7α-ol-3-one with APCI-MS/MS was >30 fold. Some sterols were
identified by comparison with authentic standards and others by information provided from
LC-ESI-MSn experiments performed with the LTQ-Orbitrap Discovery instrument.
To our knowledge measurement of elevated -C4-3-one or 5α-cholest-3-one has not been
previously described in blood or tissues from CTX patients, although these sterols are
known to be immediate precursors of 5α-cholestanol based on [14C]4-labeled C4-3-one
dosing experiments [10,11] and in vitro studies [14]. It is of interest to note that despite
comparableplasma cholesterol concentrations between CTX patients and an unaffected
subject, there is a large difference in C4-3-one concentrations (Table 1). Elevated C4-7α-
ol-3-one and 4,6-cholestadiene-3-one were previously detected in CTX serum [2] and an
alternative pathway to C4-3-one was proposed from C4-7α-ol-3-one through 4,6-
cholestadiene-3-one [9].
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In accordance with previous studies in cyp27A1 −/− mice [20], we determined the mean
plasma concentration of C4-7α-ol-3-one in 24 month old cyp27A1 −/− mice was 52% of the
plasma concentration in CTX patients, compared with a plasma concentration of 5α-
cholestanol in cyp27A1 −/− mice that was only 17% of the concentration in CTX patients.
Female 12 month old cyp27A1−/− mice were reported to display marked cerebral
accumulation of 5α-cholestanol [20], although this was small in comparison to the
accumulation in CTX patients. The difference in cerebral accumulation was hypothesized to
be due to decreased 7α-hydroxylation in the mice, with decreased transfer of C4-7α-ol-3-one
(and 7α-hydroxycholesterol) across the blood brain barrier. As the concentration of C4-7α-
ol-3-one in cyp27A1 −/− mice is around half the concentration found in CTX patients, but
the concentrations of 4,6-cholestadiene-3-one, C4-3-one and 5α-cholest-3-one range from a
quarter to a fifth, we propose differences between the cyp27A1 −/− mouse and human
disease may reside in decreased enzyme-catalyzed conversion of C4-7α-ol-3-one to 4,6-
cholestdiene-3-one and C4-3-one or more efficient removal of these sterols from the
alternative pathway to 5α-cholestanol in cyp27A1 −/− mice.
GP derivatization and LC-ESI-MSn analysis also enabled the detection in plasma of
intermediates in the neutral bile acid pathway (Figure 1). The cyp27A1 −/− mice displayed
quantitative differences in bile acid precursor profiles when compared with CTX patients,
notably decreased 12α-hydroxylated intermediates like 7α,12α-dihydroxy-4-cholesten-3-one
and 7α,12α-dihydroxy-5β-cholestan-3-one. Although 7α,12α-dihydroxy-4-cholesten-3-one,
5β-cholestan-3α,7α,12α-triol and 5β-cholestan-3α,7α-diol were previously detected at high
concentrations in plasma and liver tissue from CTX patients [4–6], to our knowledge
elevated plasma 7α,12α-dihydroxy-5β-cholestan-3-one and 7α-hydroxy-5β-cholestan-3-one
have not been previously reported.
A fragmentation route for GP-tagged 3-oxo-4-ene sterols has been proposed with the
structure for [M-79]+ ion shown as an inset to Panel A (Figure 3) [29]. GP-tagged 3-
oxo-5(H) saturated sterols fragment in an alternate manner with fragment ions observed in
the MS2 and MS3 spectra that are similar in nature. The MS2 ([M]+→) spectra are
dominated by [M-79]+ fragment ions (formation of a [M-79]+ fragment ion for GP-tagged
5α-cholestan-3-one was previously noted [29]) and the MS3 ([M]+→[M-79]+→) spectra
contain [M-107]+ ions. There is an absence of characteristic 3-oxo-4-ene b ions indicating
fragmentation likely does not involve B ring cleavage. There is also little evidence of C and
D ring cleavage, except in the case of GP-tagged 7α,12α-dihydroxy-5β-cholestan-3-one.
Modification of B and C rings by introduction of hydroxyl groups at C7 and C12 (Figure 5)
leads to formation of characteristic [M-79-(n18)]+ and [M-107-(n18)]+ fragment ions [29].
Overall less structurally informative fragments are present the MS3 spectra than for the
corresponding 3-oxo-4-enes.
A limitation of the experiments we describe was the focus on 3-oxo-4-ene and 3-oxo-5(H)
saturated sterols and bile alcohols, however these experiments could be easily modified to
also examine 3α-hydroxy-5β(H) bile alcohols present in CTX, for example 3α,7α,12α-
trihydroxy-5β-cholestane and 3α,7α-dihydroxy-5β-cholestane (by conversion to 3-
oxo-5β(H) bile alcohols using 3α-hydroxysteroid dehydrogenase as described for synthesis
of 7α,12α-dihydroxy-5β-cholestan-3-one in methods section [25]). Such experiments are
underway in our laboratory and also possess the advantage that cholesterol in the samples
remains underivatized.
In conclusion, we report here that GP derivatization of plasma and high resolution exact
mass LC-ESI-MSn analysis can be utilized to selectively profile the free 3-oxo sterol
signature present in the systemic circulation of untreated CTX patients and in cyp27A1−/−
mice, even without removal of cholesterol, which is present in great excess. The techniques
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we describe facilitate the study of sterol and bile acid pathways in CTX, and should lead to
improvements in screening, diagnosis, and treatment of this debilitating disease.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The neutral pathway to primary bile acids in cerebrotendinous xanthomatosis (CTX)
Bile acid precursors (bile alcohols) are generated by increased cholesterol 7α-hydroxylase
activity, in addition to deficient 27-hydroxylation in CTX affected patients. With CDCA
treatment of CTX the plasma concentration of 7α-hydroxy-4-cholesten-3-one (C4-7α-ol-3-
one) rapidly declines [8,9]; reflecting feedback inhibition by CDCA to decrease cholesterol
7α-hydroxylation, and limit bile acid synthesis [9]. In the normal sequence of events C4-7α-
ol-3-one can be further hydroxylated to form 7α,12α-dihydroxy-4-cholesten-3-one (C4-7α,
12α-diol-3-one). Both C4-7α,12α-diol-3-one and C4-7α-ol-3-one are reduced by a soluble 3-
oxosteroid Δ4-steroid 5β-reductase to form 7α,12α-dihydroxy-5β-cholestan-3-one and 7α-
hydroxy-5β-cholestan-3-one, respectively [9]. Prior to 27-hydroxylation the 3-oxo moiety in
each bile alcohol is further reduced by a 3α-hydroxysteroid dehydrogenase to form 5β-
cholestane-3α,7α,12α-triol and 5β-cholestane-3α,7α-diol respectively [9].
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Figure 2. 7α-Hydroxy-4-cholesten-3-one and 4-cholesten-3-one present in plasma from untreated
CTX patient and cyp27A1 −/− mice
Panel A & B and E & F are RICs from data generated in the Orbitrap analyzer for plasma
from representative unaffected human and 24 month old female wild-type mouse,
respectively. Panel C & D and G & H (upper chromatograms) are RICs for plasma from
representative CTX affected patient and 24 month old female cyp27A1 −/− mouse,
respectively. GP-tagged C4-7α-ol-3-one (exact mass 534.4054) appears in chromatograms
as syn and anti conformers eluting at 7 and 7.3 min. GP-tagged C4-3-one (exact mass
518.4105) appears in chromatograms as broad peak eluting at 8.4 min. Panel C & D and G
& H (lower chromatograms) are RICs for [2H]7-labeled C4-7α-ol-3-one (exact mass
541.4493) and [2H]7-labeled C4-3-one (exact mass 525.4544) internal standards
respectively spiked into plasma samples.
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Figure 3. Fragmentation routes for GP-tagged 3-oxo-4-ene sterols illustrated by 4-cholesten-3-
one
Panel A is MS2 (518→;upper panel) and MS3 (518→439→;lower panel) spectra for GP-
tagged C4-3-one from CTX plasma eluting at 8.4 min. Panel B is MS2 and MS3 spectra for
GP-tagged authentic standard at same retention time. Major [M-79]+ and [M-107]+ fragment
ions formed by the neutral loss of pyridine, and pyridine plus CO, respectively, are observed
in MS2 ([M]+→) spectra; structure for [M-79]+ ion is shown as inset to Panel A [29].
Formation of structurally informative fragment ions observed in MS3 ([M]+→[M-79]+→)
spectra are indicated according to Griffiths et al [29]. MSn spectra were generated in LIT
analyzer.
                      
                                                                                               
 
  
            
         
 
  
            
         
 
  
            
         
Figure 4. 5α-Cholestan-3-one present in plasma from untreated CTX patient
Panels A and B are RICs from data generated in the Orbitrap analyzer for representative
CTX plasma sample and authentic standard, respectively. GP-tagged 5α-cholestan-3-one
appears in chromatogram as broad peak eluting at 8 min. Panels C are MS2 (520→;upper
panel) and MS3 (520→441→;lower panel) spectra for GP-tagged 5α-cholestan-3-one from
CTX plasma. Panels D are MS2 and MS3 spectra for GP-tagged authentic 5α-cholestan-3-
one. Collision induced dissociation of [M-79]+ ion observed in MS2 spectra leads to
formation of two ions in MS3 spectra; m/z 413 corresponding to loss of pyridine plus CO
[M-107]+ and m/z 398, likely arising from loss of pyridine plus isocyanic acid [M-79-
HNCO]+.
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Figure 5. 7α,12α-Dihydroxy-4-cholesten-3-one and 7α,12α-dihydroxy-5β-cholestan-3-one present
in plasma from untreated CTX patient
Panels A and B are RICs from data generated in the Orbitrap analyzer for plasma from
representative un-affected and CTX affected subject, respectively. Left panels; putative GP
tagged 7α,12α-dihydroxy-4-cholesten-3-one appears in chromatogram as syn and anti
conformer split peak eluting at 6.2–6.3 min. Right panels; GP-tagged 7α,12α-dihydroxy-5β-
cholestan-3-one appears in chromatogram as peak eluting at 6.6 min (peak at 6.4 min is
unidentified putative dihydroxy-5β-cholestan-3-one). Panels C are respective MS2 spectra
(550→left panel, 552→right panel) and Panels D are respective MS3 spectra
(550→471→left panel; 552→473→left panel). Formation of structurally informative
fragment ions observed in MS3 spectra for 7α,12α-dihydroxy-4-cholesten-3-one [M-79]+ ion
are indicated (inset to Panel C); including *b3-C2H4 fragment observed at m/z 179
indicating presence of 7α-hydroxyl group [29]. There is no *c2+2H-H2O fragment observed
at m/z 231 (from cleavage of C-ring) [29], indicating C-ring is modified, likely with 12α-
hydroxyl group. The presence of two hydroxyl groups is consistent with observation of
characteristic [M-79-(nH2O)]+ and [M-107-(nH2O)]+ ions [29]. GP-tagged 7α,12α-
dihydroxy-5β-cholestan-3-one from CTX plasma was identified by comparison to GP-
tagged authentic standard. Fragment ions observed in the MS3 spectrum include m/z [M-79-
(nH2O)]+ and [M-107-(nH2O)]+ ions indicative of two hydroxyl groups. Low abundance
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ions at m/z 392 and 394 most likely arise from neutral loss of pyridine, NH3, CO and two
molecules of water [M-79-NH3-CO-2H2O]+ and loss of pyridine, isocyanic acid and water
[M-79-HNCO-2H2O]+, respectively.
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 3
02
 (9
18
–1
58
0)
34
2 
± 
90
 (2
67
–4
61
)
30
40
 ±
 9
10
 (2
51
0–
44
00
)
14
8 
± 
11
 (1
32
–1
56
)
Re
pr
es
en
ta
tiv
e 
un
af
fe
ct
ed
 su
bj
ec
t
14
8
94
N
D
22
0e
15
1
Fe
m
al
e 
cy
p2
7A
1−
/−
 m
ic
e 
(n
=3
)
38
97
 ±
 1
95
2 
(2
74
0–
61
50
)
17
0 
± 
49
 (1
13
–2
01
)
71
 ±
 1
0 
(4
8–
83
)
32
9 
± 
10
8 
(2
24
–4
40
)
36
 ±
11
 (2
6–
48
)
Fe
m
al
e 
cy
p2
7A
1+
/+
 m
ic
e 
(n
=3
)
25
8 
± 
12
4 
(1
38
–3
85
)
42
 ±
 1
6 
(2
5–
55
)
37
 ±
 1
0 
(2
7–
46
)
22
8 
± 
96
 (1
71
–3
39
)
86
 ±
 4
2 
(5
6–
13
4)
M
al
e 
cy
p2
7A
1−
/−
 m
ic
e 
(n
=3
)
20
18
 ±
 1
55
5 
(6
94
–3
73
0)
11
5 
± 
42
 (8
3–
16
2)
97
 ±
 1
4 
(8
5–
11
2)
70
6 
± 
19
8 
(5
18
–9
13
)
70
 ±
 8
 (6
5–
79
)
M
al
e 
cy
p2
7A
1+
/+
 m
ic
e 
(n
=3
)
14
0 
± 
11
5 
(6
5–
27
2)
17
 ±
 2
0 
(6
–4
1)
63
 ±
 1
5 
(4
8–
78
)
40
5 
± 
58
 (3
44
–4
60
)
64
 ±
 1
5 
(5
0–
79
)
M
ea
n 
± 
S.
D
. a
nd
 (r
an
ge
 o
f r
es
ul
ts
) a
re
 g
iv
en
; N
D
, n
ot
 d
et
ec
te
d.
a A
na
ly
si
s p
er
fo
rm
ed
 w
ith
 4
00
0 
Q
TR
A
P 
in
st
ru
m
en
t s
ca
nn
in
g 
in
 tr
ip
le
-q
ua
d 
m
od
e.
b F
re
e 
st
er
ol
; q
ua
nt
ifi
ca
tio
n 
ba
se
d 
on
 a
re
a 
ra
tio
 o
f 7
α-
hy
dr
ox
y-
4-
ch
ol
es
te
n-
3-
on
e 
to
 7
α-
hy
dr
ox
y-
4-
ch
ol
es
te
n-
3-
on
e-
d 7
 in
te
rn
al
 st
an
da
rd
 sy
nt
he
si
ze
d 
as
 d
es
cr
ib
ed
 p
re
vi
ou
sl
y 
[8
].
c F
re
e 
st
er
ol
s;
 q
ua
nt
ifi
ca
tio
n 
w
as
 b
as
ed
 o
n 
ar
ea
 ra
tio
 o
f s
te
ro
l t
o 
4-
ch
ol
es
te
n-
3-
on
e-
d 7
 in
te
rn
al
 st
an
da
rd
.
d L
LO
Q
 fo
r C
4-
3-
on
e 
50
ng
/m
l, 
fo
r 5
α-
ch
ol
es
ta
n-
3-
on
e 
10
0n
g/
m
l.
e H
yd
ro
ly
ze
d 
st
er
ol
s;
 q
ua
nt
ifi
ca
tio
n 
w
as
 b
y 
G
C
-F
ID
 a
nd
 G
S-
M
S.
f N
or
m
al
ly
 <
60
0 
μg
/d
l a
nd
 fo
r C
TX
 b
et
w
ee
n 
1,
30
0–
15
,0
00
 μ
g/
dl
 [9
].
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